Parathyroid Hormone as a Treatment for Osteoporosis

Eric C. Buxton, Iljie Kim Fitzgerald, Nancy E Lane

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Current medical therapies to treat osteoporosis, including both anti-resorptive and anabolic agents, are aimed at correcting the imbalance between bone resorption and bone formation. The newest and most promising anabolic treatment to date is the use of intermittent, subcutaneous fragments of recombinant human parathyroid hormone (rhPTH, teriparatide, Forteo™). Administered as monotherapy, this well-tolerated treatment significantly increased bone mineral density (BMD) of the lumber spine, femoral neck and total body in women with postmenopausal osteoporosis, and reduced the risk of vertebral and non-vertebral fractures. Teriparatide administered in combination with hormone replacement therapy (HRT) in postmenopausal women resulted in significantly increased bone mass in the lumbar spine, total hip and total body compared with HRT alone, and was accompanied by dramatic reductions in the incidence of vertebral fractures. Preliminary studies of a treatment regimen combining teriparatide and the anti-resorptive bisphosphonate alendronate showed no alteration in hPTH's known anabolic effect on vertebral BMD, and a slight improvement in total hip, total body, and radial diaphysis BMD compared to hPTH alone. Finally, early studies in men suggest that teriparatide in combination with a bisphosphonate appears to be of clinical benefit in reducing the risk of male osteoporotic fractures as well. In summary, multiple clinical trials have documented the safety and efficacy of teriparatide, both as monotherapy and in combination with bisphosphonates, HRT and calcitonin, for the treatment of osteoporosis.

Original languageEnglish (US)
Pages (from-to)345-372
Number of pages28
JournalToday's Therapeutic Trends
Volume21
Issue number4
StatePublished - Dec 2003
Externally publishedYes

Fingerprint

Teriparatide
Parathyroid Hormone
Osteoporosis
Diphosphonates
Bone Density
Anabolic Agents
Hormone Replacement Therapy
Hip
Spine
Therapeutics
Bone and Bones
Alendronate
Diaphyses
Postmenopausal Osteoporosis
Osteoporotic Fractures
Estrogen Replacement Therapy
Femur Neck
Calcitonin
Bone Resorption
Osteogenesis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Parathyroid Hormone as a Treatment for Osteoporosis. / Buxton, Eric C.; Fitzgerald, Iljie Kim; Lane, Nancy E.

In: Today's Therapeutic Trends, Vol. 21, No. 4, 12.2003, p. 345-372.

Research output: Contribution to journalArticle

Buxton, EC, Fitzgerald, IK & Lane, NE 2003, 'Parathyroid Hormone as a Treatment for Osteoporosis', Today's Therapeutic Trends, vol. 21, no. 4, pp. 345-372.
Buxton, Eric C. ; Fitzgerald, Iljie Kim ; Lane, Nancy E. / Parathyroid Hormone as a Treatment for Osteoporosis. In: Today's Therapeutic Trends. 2003 ; Vol. 21, No. 4. pp. 345-372.
@article{cb9bad3fee42449591ff4a9599e64228,
title = "Parathyroid Hormone as a Treatment for Osteoporosis",
abstract = "Current medical therapies to treat osteoporosis, including both anti-resorptive and anabolic agents, are aimed at correcting the imbalance between bone resorption and bone formation. The newest and most promising anabolic treatment to date is the use of intermittent, subcutaneous fragments of recombinant human parathyroid hormone (rhPTH, teriparatide, Forteo™). Administered as monotherapy, this well-tolerated treatment significantly increased bone mineral density (BMD) of the lumber spine, femoral neck and total body in women with postmenopausal osteoporosis, and reduced the risk of vertebral and non-vertebral fractures. Teriparatide administered in combination with hormone replacement therapy (HRT) in postmenopausal women resulted in significantly increased bone mass in the lumbar spine, total hip and total body compared with HRT alone, and was accompanied by dramatic reductions in the incidence of vertebral fractures. Preliminary studies of a treatment regimen combining teriparatide and the anti-resorptive bisphosphonate alendronate showed no alteration in hPTH's known anabolic effect on vertebral BMD, and a slight improvement in total hip, total body, and radial diaphysis BMD compared to hPTH alone. Finally, early studies in men suggest that teriparatide in combination with a bisphosphonate appears to be of clinical benefit in reducing the risk of male osteoporotic fractures as well. In summary, multiple clinical trials have documented the safety and efficacy of teriparatide, both as monotherapy and in combination with bisphosphonates, HRT and calcitonin, for the treatment of osteoporosis.",
author = "Buxton, {Eric C.} and Fitzgerald, {Iljie Kim} and Lane, {Nancy E}",
year = "2003",
month = "12",
language = "English (US)",
volume = "21",
pages = "345--372",
journal = "Today's Therapeutic Trends",
issn = "0741-2320",
publisher = "Communications Media for Education,Inc",
number = "4",

}

TY - JOUR

T1 - Parathyroid Hormone as a Treatment for Osteoporosis

AU - Buxton, Eric C.

AU - Fitzgerald, Iljie Kim

AU - Lane, Nancy E

PY - 2003/12

Y1 - 2003/12

N2 - Current medical therapies to treat osteoporosis, including both anti-resorptive and anabolic agents, are aimed at correcting the imbalance between bone resorption and bone formation. The newest and most promising anabolic treatment to date is the use of intermittent, subcutaneous fragments of recombinant human parathyroid hormone (rhPTH, teriparatide, Forteo™). Administered as monotherapy, this well-tolerated treatment significantly increased bone mineral density (BMD) of the lumber spine, femoral neck and total body in women with postmenopausal osteoporosis, and reduced the risk of vertebral and non-vertebral fractures. Teriparatide administered in combination with hormone replacement therapy (HRT) in postmenopausal women resulted in significantly increased bone mass in the lumbar spine, total hip and total body compared with HRT alone, and was accompanied by dramatic reductions in the incidence of vertebral fractures. Preliminary studies of a treatment regimen combining teriparatide and the anti-resorptive bisphosphonate alendronate showed no alteration in hPTH's known anabolic effect on vertebral BMD, and a slight improvement in total hip, total body, and radial diaphysis BMD compared to hPTH alone. Finally, early studies in men suggest that teriparatide in combination with a bisphosphonate appears to be of clinical benefit in reducing the risk of male osteoporotic fractures as well. In summary, multiple clinical trials have documented the safety and efficacy of teriparatide, both as monotherapy and in combination with bisphosphonates, HRT and calcitonin, for the treatment of osteoporosis.

AB - Current medical therapies to treat osteoporosis, including both anti-resorptive and anabolic agents, are aimed at correcting the imbalance between bone resorption and bone formation. The newest and most promising anabolic treatment to date is the use of intermittent, subcutaneous fragments of recombinant human parathyroid hormone (rhPTH, teriparatide, Forteo™). Administered as monotherapy, this well-tolerated treatment significantly increased bone mineral density (BMD) of the lumber spine, femoral neck and total body in women with postmenopausal osteoporosis, and reduced the risk of vertebral and non-vertebral fractures. Teriparatide administered in combination with hormone replacement therapy (HRT) in postmenopausal women resulted in significantly increased bone mass in the lumbar spine, total hip and total body compared with HRT alone, and was accompanied by dramatic reductions in the incidence of vertebral fractures. Preliminary studies of a treatment regimen combining teriparatide and the anti-resorptive bisphosphonate alendronate showed no alteration in hPTH's known anabolic effect on vertebral BMD, and a slight improvement in total hip, total body, and radial diaphysis BMD compared to hPTH alone. Finally, early studies in men suggest that teriparatide in combination with a bisphosphonate appears to be of clinical benefit in reducing the risk of male osteoporotic fractures as well. In summary, multiple clinical trials have documented the safety and efficacy of teriparatide, both as monotherapy and in combination with bisphosphonates, HRT and calcitonin, for the treatment of osteoporosis.

UR - http://www.scopus.com/inward/record.url?scp=0242299664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242299664&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0242299664

VL - 21

SP - 345

EP - 372

JO - Today's Therapeutic Trends

JF - Today's Therapeutic Trends

SN - 0741-2320

IS - 4

ER -